Anticoagulant News and Research RSS Feed - Anticoagulant News and Research

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix Corp. today announced that it has entered into a Framework Agreement which sets forth the principal business terms for an equity investment and a license of RVX-208, for all indications, to Shenzhen Hepalink Pharmaceutical Co., Ltd. for China, Hong Kong, Taiwan and Macau (the "Territories"). [More]
Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse). [More]
Study looks at dabigatran adherence across Veterans Health Administration sites

Study looks at dabigatran adherence across Veterans Health Administration sites

Among patients with atrial fibrillation who filled prescriptions for the anticoagulant dabigatran at Veterans Health Administration sites, there was variability in patient medication adherence across sites, with appropriate patient selection and pharmacist-led monitoring associated with greater adherence to the medication, according to a study in the April 14 issue of JAMA. [More]
Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics, Inc. today announced longer-term data from a Phase II investigator-initiated study showing Waldenstrom's macroglobulinemia (WM) patients treated with IMBRUVICA (ibrutinib) experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of treatment and a 2-year overall survival (OS) rate of 95%. [More]
Northwestern University researchers find safer way to improve surgery outcomes

Northwestern University researchers find safer way to improve surgery outcomes

A Northwestern University research team potentially has found a safer way to keep blood vessels healthy during and after surgery. [More]
New article highlights need for optimization of warfarin therapy

New article highlights need for optimization of warfarin therapy

Warfarin can be a challenging drug to manage. Long-term anticoagulation is recommended for patients with atrial fibrillation at risk of stroke, and for those with recurrent venous thrombosis or prosthetic heart valves. [More]
Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

This week, three patients in the United States received the first implants of the Boston Scientific Corporation WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device. [More]
Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints--a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding--as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
Using arm as access point for catheter-based heart procedures lowers risk of major bleeding, death

Using arm as access point for catheter-based heart procedures lowers risk of major bleeding, death

Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
New anti-clotting therapy no better than established anticoagulants

New anti-clotting therapy no better than established anticoagulants

A novel therapy that would allow doctors to turn the body's blood-clotting ability off and on in a more controlled way was about as effective as established anticoagulants in patients undergoing angioplasty but was associated with higher rates of moderate to severe bleeding, according to an analysis of data from a terminated Phase III trial presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA. [More]
Janssen announces acquisition of XO1

Janssen announces acquisition of XO1

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab. [More]
Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced today that its lead compound tacrolimus (SPI-026) has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for the treatment of pulmonary arterial hypertension (PAH). [More]
New ASH report outlines several models for 'systems-based clinical hematologist'

New ASH report outlines several models for 'systems-based clinical hematologist'

A report released today from the American Society of Hematology in its journal, Blood, presents an innovative, sustainable new role for hematologists, particularly those specializing in non-malignant blood diseases, for today’s rapidly changing U.S. health-care system. [More]
New blood thinner reduces stroke risk in patients with atrial fibrillation

New blood thinner reduces stroke risk in patients with atrial fibrillation

Patients with high-risk atrial fibrillation, or AFib, often require one drug to regulate heart rhythm and a second drug to thin their blood and reduce the risk of stroke. [More]
New guidelines advise nearly all women, people with AFib to take blood thinners

New guidelines advise nearly all women, people with AFib to take blood thinners

Nearly all women and people over 65 in the U.S. with atrial fibrillation are advised to take blood thinners under new guidelines based on an analysis from the Duke Clinical Research Institute. [More]
Study finds new approaches to manage anticoagulant-associated intracerebral hemorrhage

Study finds new approaches to manage anticoagulant-associated intracerebral hemorrhage

Among patients with oral anticoagulation-associated intracerebral hemorrhage (bleeding within the brain), reversal of international normalized ratio (INR; a measure used to determine the clotting tendency of blood while on medication) below a certain level within 4 hours and systolic blood pressure less than 160 mm Hg at 4 hours were associated with lower rates of hematoma (a localized swelling filled with blood) enlargement, and resumption of anticoagulant therapy was associated with a lower risk of ischemic events without increased bleeding complications, according to a study in the February 24 issue of JAMA. [More]
PCDS AC system optimizes delivery of anticoagulation drugs, reduces adverse events

PCDS AC system optimizes delivery of anticoagulation drugs, reduces adverse events

Point of Care Anticoagulation software (PCDS AC) optimizes delivery of anticoagulation drugs and reduces adverse events associated with anticoagulation therapy. The software was designed and developed in collaboration with leading clinical thrombosis experts, and is a decision support tool that takes the complexity out of AC management by providing a real-time AC dashboard. With intuitive, predictive clinical decision support, PCDS AC transforms evidence-based guidelines into intelligent tools that measure and improve AC therapy outcomes. [More]
Anticoagulant fondaparinux lowers risk of major bleeding events, death in heart attack patients

Anticoagulant fondaparinux lowers risk of major bleeding events, death in heart attack patients

Patients who experienced a certain type of heart attack who received the anticoagulant fondaparinux had a lower risk of major bleeding events and death both in the hospital and after six months compared to patients who received low-molecular-weight heparin (LMWH), although both groups had similar rates of subsequent heart attack or stroke, according to a study in the February 17 issue of JAMA. [More]
Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals plc announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease (VOD), a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy. [More]
Advertisement
Advertisement